Waters Corporation delivered a strong finish to 2025 with Q4 sales of $932 million (+7% reported, +6% constant currency) and adjusted EPS of $4.53 (+10%). For the full year, sales grew 7% to approximately $3.4 billion, with adjusted EPS increasing 11% to $13.13, driven by high single-digit pharma growth and a 9% increase in recurring revenue. The quarter marked the transformative close of the BD Biosciences and Diagnostic Solutions acquisition, creating a new scientific powerhouse with four divisions. Management provided 2026 guidance for the combined company, projecting revenue of $6.405 billion to $6.455 billion and adjusted EPS of $14.30 to $14.50, representing approximately 9-10% EPS growth and immediate accretion. Key growth drivers include GLP-1s, PFAS testing, and India generics, while the transition of Empower to a subscription model is expected to drive long-term recurring revenue despite short-term headwinds.
| Metric | Value | Change |
|---|---|---|
| Q4 Sales | $932 million | +7% Reported / +6% CC |
| Q4 Adjusted EPS | $4.53 | +10% |
| FY 2025 Sales Growth | 7% | 7% Reported / 7% CC |
| FY 2025 Adjusted EPS | $13.13 | +11% |
| Q4 Recurring Revenue Growth | 9% | +9% |
| Q4 Instrument Sales Growth | 3% | +3% |
| Service Plan Attachment Rate | 54% | +400 bps YoY |
The completion of the BD Biosciences and Diagnostic Solutions acquisition represents a transformative shift, expanding Waters into high-growth adjacencies like flow cytometry and microbiology. Management has reorganized the company into four divisions (Analytical Sciences, Biosciences, Advanced Diagnostics, Material Sciences) to enhance accountability. They expect immediate accretion of $0.10 in EPS in year one and have outlined a clear path to $55 million in cost synergies and $50 million in revenue synergies for 2026, leveraging their operational playbook.
Waters is executing a strategic shift of its Empower software from a license-based model to a subscription-based model. While this transition created a low single-digit headwind to instrument revenue in Q4, management emphasizes it builds a higher-quality recurring revenue stream. They project the informatics business will grow from ~$300 million to ~$500 million by 2030, with the breakeven on cumulative subscription revenue occurring around 18 months, driving accretive tailwinds starting in 2027.
Management is aggressively applying its 'Waters playbook' of operational discipline to the newly acquired businesses. This includes implementing a centralized 'deal desk' to enforce pricing discipline and discounting policies, which historically drove 200-400 basis points of pricing improvement at Waters. They also plan to drive service attachment rates (currently 40% at BD vs 54% at Waters) and e-commerce adoption, creating a clear roadmap for margin expansion and revenue synergies.
The company is expanding its 'idiosyncratic growth driver' framework from three to five drivers, adding Biologics and Informatics to GLP-1s, PFAS, and India generics. These drivers contributed over 300 basis points of growth in 2025, with GLP-1 revenue doubling and PFAS testing growing over 40%. Management expects these five drivers to contribute over 200 basis points of annual revenue growth accretion through 2030, supporting a long-term outlook of sustainable high single-digit growth.
The acquired BD Biosciences and Diagnostic Solutions business faced significant deterioration in Q4, with results coming in 'below expectations.' Headwinds included China DRG pricing pressure, a milder flu season impacting point-of-care testing, and U.S. government shutdowns delaying export approvals. Management had to 'risk-adjust' the 2026 outlook to a conservative 2.5% underlying growth for these assets, raising concerns about the integration complexity and the health of the acquired portfolio.
TA Instruments, now part of the Material Sciences division, experienced a decline in Q4 due to cautious spending in the U.S. and Europe. While there was an improvement versus the first half of the year, the weakness in this segment highlights ongoing sensitivity in industrial and academic capital expenditure environments, which could persist if macroeconomic conditions worsen.
The transition of Empower to a subscription model is creating tangible short-term headwinds, reducing overall instrument growth by a low single-digit percentage in Q4. While management frames this as a 'fantastic problem to have,' the shift in revenue timing from upfront CapEx to recurring streams creates a near-term gap that must be filled by other growth drivers to meet the aggressive 5.5-7% organic growth targets.
Academic and Government (A&G) end markets showed weakness, declining 3% in Q4 and 1% for the full year. Management noted 'spending declines' in these regions outside of the Americas. This softness, combined with the cautious spending impacting TA Instruments, suggests a potential fragility in the broader instrument market demand outside of the company's specific idiosyncratic drivers.
Overall: Management exhibited a tone of disciplined confidence and operational rigor throughout the call. While acknowledging recent underperformance in the acquired BD business, they framed it as a 'prudent' baseline for future upside, emphasizing their proven playbook for fixing execution. They were highly specific about synergy targets and growth drivers, suggesting a high level of control over the integration process.
Confidence: HIGH - Management provided precise synergy figures ($55M cost, $50M revenue), detailed integration plans, and reaffirmed long-term margin algorithms despite near-term acquisition headwinds. Their use of definitive language regarding the 'industry-leading' nature of their growth and 'strong momentum' in Q1 reinforces high confidence.
$6.405 billion - $6.455 billion
5.5% - 7% (Constant Currency)
$14.30 - $14.50
28.1%
$1.198 billion - $1.211 billion
$2.25 - $2.35
Hedging & Uncertainty: Management frequently utilized the term 'prudent' and its variants to frame their guidance and assumptions, signaling a conservative approach to the integration. Phrases like 'prudent starting point,' 'prudently assumes,' and 'risk-adjusted' were used to lower expectations for the acquired BD business performance. However, they balanced this hedging with strong confidence markers regarding their own execution capabilities, using 'confident,' 'strong momentum,' and 'industry-leading' to describe the core business and synergy targets. This pattern suggests they are managing expectations for the acquired assets while assuring investors of their ability to fix them.
Our growth outlook of 5.3% at midpoint for the combined company is appropriately prudent, yet industry-leading. - Udit Batra, CEO
It's a fantastic problem to have, right? Two of the top 5 pharmas converted. - Amol Chaubal, CFO
We are entering this chapter from a position of strength. - Udit Batra, CEO
We feel very good about where we're starting with the guide. - Udit Batra, CEO
There is zero reason why there should be discounting there. - Udit Batra, CEO
This reminds me of Waters almost 5 years ago. - Udit Batra, CEO
Analyst Sentiment: Analysts expressed skepticism regarding the deterioration of the acquired BD business relative to the original deal model, specifically probing the path to recovery in lagging areas like U.S. academic/government and China. There was also significant focus on the mechanics of the Empower subscription transition and its impact on the P&L.
Management Responses: Management remained disciplined and defensive regarding the BD business, repeatedly pointing to the 'prudent' nature of their guidance and the 'upside' potential from applying their operational playbook. They deflected concerns about the BD assets by comparing the situation to Waters' own turnaround five years ago, emphasizing their ability to execute on pricing and service attachments.
Analysis of BD Biosciences/Diagnostics underperformance and recovery path.
Impact of Empower subscription transition on instrument revenue and recurring revenue.
Detailed breakdown of synergy targets (cost vs. revenue) and the 'deal desk' implementation.
Pricing power and margin expansion potential in the chemistry and reagent businesses.
Leverage and interest expense assumptions for the combined entity.
Waters Corporation is executing at a high level with its core business delivering 7% top-line growth and double-digit EPS expansion. The close of the BD Biosciences acquisition is a transformative event that immediately diversifies the company into high-growth adjacencies like flow cytometry and diagnostics. While the acquired assets face near-term headwinds (China DRG, flu season), Waters' management has a proven track record of operational excellence, specifically in pricing discipline and service attach, which they are already deploying to unlock value. The 2026 guidance implies immediate accretion and margin expansion, and the shift to a recurring revenue model via Empower subscriptions sets the company up for sustainable long-term growth. The risk of integration is mitigated by the 'prudent' baseline set by management, leaving significant room for upside as execution improves.
Management noted 'weakened demand' in China due to increased focus on reducing consumption in diagnostics testing (DRG), specifically impacting the acquired BD business. This headwind has been baked into the 2026 guidance as a prudent assumption.
The Biosciences business was impacted by a U.S. government shutdown which delayed export approvals. This caused a temporary disruption in Q4 but is not expected to be a recurring issue for 2026.
Pharma end markets showed resilience with 9% growth for the full year. Management highlighted 'strong momentum' in biotech and CDMOs, particularly in China, and continued wins in GLP-1 manufacturing and development.
Industrial markets grew 6% for the year, driven by 'double-digit strength' in chemical analysis, food, and environmental testing. PFAS testing demand remained robust, growing over 40% year-over-year.